For the 100th time, financing is good even WITH trials starting per Missling. If you don't believe it or doubt it, then why invest in a ticker that you have no trust in the CEO to execute his job.
I find the 6 sustained patients encouraging. If the company is representing the concentration and disease severity dependencies accurately (no correlation data on the 6, so I can't attest) then it's a glimmer of potential efficacy and important future trial design.